Received a patent grant. Under an exclusive license with re-grantable sublicensing rights from Keio University, the IP foundation for the regenerative medicine pipeline centered on KP8011, including NeuroSphere manufacturing, selection, and therapeutic cell quality improvement, has been strengthened. Preparation for corporate clinical trials is progressing with a target start in 2027; overseas filings are ongoing. No impact on earnings forecasts for the fiscal year ending December 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4896","jir_company_name":"K Pharma,Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-10-14","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4896-20261014-01.pdf","jir_short_summary":"Received a patent grant. Under an exclusive license with re-grantable sublicensing rights from Keio University, the IP foundation for the regenerative medicine pipeline centered on KP8011, including NeuroSphere manufacturing, selection, and therapeutic cell quality improvement, has been strengthened. Preparation for corporate clinical trials is progressing with a target start in 2027; overseas filings are ongoing. No impact on earnings forecasts for the fiscal year ending December 2026.","jir_summary":"### Key Points\nToday we announce that a domestic patent related to our regenerative medicine business has been granted. We have received an exclusive license with re-grantable sublicensing rights from Keio University, the applicant, which strengthens the IP foundation contributing to the manufacture, selection, and quality improvement of therapeutic cells for NeuroSphere centered on KP8011. Overseas filings are also in progress. We are advancing preparations for corporate clinical trials with the aim of starting trials in 2027.\n\n### Outlook and Impact\nBy leveraging patents related to KP8011, we plan to accelerate corporate clinical trials and partnership activities. We expect to submit clinical trial notifications in 2027 and will pursue partnership negotiations with pharmaceutical companies to promote the early practical application of regenerative medicine products. This patent grant is expected to further strengthen the IP foundation of the regenerative medicine business and contribute to the long-term competitiveness of the business.","jir_financial_highlights":"Change in Earnings Forecast: Unknown (Unknown)","jir_category":"","jir_hashtags":"#RegenerativeMedicine, #IPStrategy","jir_key_figures":"Validity period and scope of granted patent: Unknown\nPlanned start of clinical trials: During 2027\nChange to earnings forecast for fiscal year ending December 2026: None","jir_meta_title":"K Pharma,Inc. Receives Patent Grant for Regenerative Medicine\uff5cPreparing KP8011-related Clinical Trials in 2027","jir_meta_description":"K Pharma,Inc. has received a domestic patent grant related to its regenerative medicine business. The company obtained an exclusive license with re-grantable sublicensing rights from Keio University, strengthening the IP foundation for NeuroSphere centered on KP8011. Corporate clinical trials are planned to start in 2027.","jir_og_title":"K Pharma,Inc. Receives Patent Grant for Regenerative Medicine\uff5cClinical Trials Planned for 2027","jir_og_description":"Strengthening of IP foundation for regenerative medicine. Obtained a patent grant with an exclusive license from Keio University. Preparing KP8011-related corporate clinical trials to begin in 2027.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59253,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"corporate_restructuring","footnotes":""},"sector":[],"importance":[],"class_list":["post-130065","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n